Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Feb 19, 2026 · Filed Feb 20, 2026
Quest Diagnostics's Regional Businesses sold $294K of Quest Diagnostics shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$293,521
Shares × reported transaction price
9 days after results of Feb 10, 2026, 61 days before results of Apr 21, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $202.44 on Feb 19, 2026, within 4% of its 52-week high, after a 12% rise over the previous 30 trading days
52-week range $159.80 (Apr 8, 2025) to $209.32 (Feb 11, 2026), 86% of the way up, from 251 adjusted closes. 30 trading days earlier: $180.46 on Jan 6, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.4% | +0.6% | +0.8% |
| 30 days | -5.3% | -3.8% | -1.5% |
| 90 days | -7.0% | +10.0% | -17.0% |
| 180 days | +17.6% | +11.9% | +5.7% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Routine share withholding; mechanical by default.